U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H18FN3O2
Molecular Weight 303.3314
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EZOGABINE

SMILES

CCOC(=O)NC1=CC=C(NCC2=CC=C(F)C=C2)C=C1N

InChI

InChIKey=PCOBBVZJEWWZFR-UHFFFAOYSA-N
InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21686305; https://www.ncbi.nlm.nih.gov/pubmed/?term=22221318

Ezogabine (U.S. adopted name) or retigabine (international nonproprietary name) is one of a family of aminopyrroles with anticonvulsant activity. It is used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was approved by the European Medicines Agency under the trade name Trobalt and by the United States Food and Drug Administration (FDA), under the trade name Potiga. The mechanism by which ezogabine exerts its therapeutic effects has not been fully elucidated. In vitro studies indicate that ezogabine enhances transmembrane potassium currents mediated by the KCNQ (Kv7.2 to 7.5) family of ion channels. By activating KCNQ channels, ezogabine is thought to stabilize the resting membrane potential and reduce brain excitability. This mechanism of action is unique among antiepileptic drugs, and may hold promise for the treatment of other neurologic conditions, including migraine, tinnitus and neuropathic pain. In vitro studies suggest that ezogabine may also exert therapeutic effects through augmentation of GABA-mediated currents.

CNS Activity

CNS Penetrant
2554
Curator's Comment: Ezogabine can cross the blood–brain barrier and is not subject to P-glycoprotein active transport across this barrier, free brain concentrations will closely follow free plasma concentrations.

Originator

Valeant|GlaxoSmithKline
3
Curator's Comment: # Valeant Pharmaceuticals International and GlaxoSmithKline

Approval Year

2011
587
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1430
 1.6 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8429
POTIGA

Approved Use

Indicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity

Launch Date

2011
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
414 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
498 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
551.9 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
561 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
819 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
842 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
993 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
250 mg 2 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
978 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
728.8 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
938.7 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1831 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1914 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3972.5 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
4393.8 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5134 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5136 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5184 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
250 mg 2 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5279 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7355.9 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7895.9 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.4 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.2 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.4 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.9 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.8 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
250 mg 2 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.57 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.28 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EZOGABINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
Doses

Doses

DosePopulationAdverse events​
350 mg 3 times / day multiple, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: multiple
Dose: 350 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25006968
unhealthy, 30 years
n = 2
Health Status: unhealthy
Condition: epilepsy
Age Group: 30 years
Sex: F
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/25006968
Disc. AE: Mucocutaneous disorder...
AEs leading to
discontinuation/dose reduction:
Mucocutaneous disorder (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/25006968
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Disc. AE: Dizziness, Confusional state...
Other AEs: Urinary tract infection, Influenza...
AEs leading to
discontinuation/dose reduction:
Dizziness (9.2%)
Confusional state (6.5%)
Ataxia (2.6%)
Somnolence (3.9%)
Dysarthria (2.6%)
Headache (1.3%)
Fatigue (3.3%)
Vision blurred (1.3%)
Tremor (2.6%)
Nausea (2.6%)
Speech disorder (0.7%)
Memory impairment (0.7%)
Diplopia (2%)
Gait disturbance (1.3%)
Balance disorder (0.7%)
Vomiting (1.3%)
Anxiety (1.3%)
Disturbance in attention (2%)
Other AEs:
Urinary tract infection (11.8%)
Influenza (7.8%)
Constipation (5.9%)
Urinary hesitation (5.9%)
Dysuria (5.2%)
Disorientation (5.2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
50 mg 3 times / day multiple, oral (starting)
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/26909536
unhealthy, 48 years
n = 1
Health Status: unhealthy
Condition: epilepsy
Age Group: 48 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/26909536
Disc. AE: Maculopathy...
AEs leading to
discontinuation/dose reduction:
Maculopathy (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26909536
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
unhealthy, adult
n = 813
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 813
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
Disc. AE: Dizziness, Confusional state...
AEs leading to
discontinuation/dose reduction:
Dizziness (6%)
Confusional state (4%)
Fatigue (3%)
Somnolence (3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
2500 mg 1 times / day multiple, oral
Overdose
Dose: 2500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2500 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
unhealthy
Health Status: unhealthy
Condition: epilepsy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
Other AEs: Agitation, Aggressive behavior...
Other AEs:
Agitation
Aggressive behavior
Irritability
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Mucocutaneous disorder 2 patients
Disc. AE
350 mg 3 times / day multiple, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: multiple
Dose: 350 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25006968
unhealthy, 30 years
n = 2
Health Status: unhealthy
Condition: epilepsy
Age Group: 30 years
Sex: F
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/25006968
Balance disorder 0.7%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Memory impairment 0.7%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Speech disorder 0.7%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Anxiety 1.3%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Gait disturbance 1.3%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Headache 1.3%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Vision blurred 1.3%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Vomiting 1.3%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Urinary tract infection 11.8%
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Diplopia 2%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Disturbance in attention 2%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Ataxia 2.6%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Dysarthria 2.6%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Nausea 2.6%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Tremor 2.6%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Fatigue 3.3%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Somnolence 3.9%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Disorientation 5.2%
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Dysuria 5.2%
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Constipation 5.9%
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Urinary hesitation 5.9%
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Confusional state 6.5%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Influenza 7.8%
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Dizziness 9.2%
Disc. AE
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
unhealthy, 37.7 years (range: 18 –71 years)
n = 153
Health Status: unhealthy
Condition: drug-resistant partial epilepsy
Age Group: 37.7 years (range: 18 –71 years)
Sex: M+F
Population Size: 153
Sources:
https://pubmed.ncbi.nlm.nih.gov/21451152
Maculopathy 1 patient
Disc. AE
50 mg 3 times / day multiple, oral (starting)
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/26909536
unhealthy, 48 years
n = 1
Health Status: unhealthy
Condition: epilepsy
Age Group: 48 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/26909536
Fatigue 3%
Disc. AE
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
unhealthy, adult
n = 813
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 813
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
Somnolence 3%
Disc. AE
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
unhealthy, adult
n = 813
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 813
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
Confusional state 4%
Disc. AE
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
unhealthy, adult
n = 813
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 813
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
Dizziness 6%
Disc. AE
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
unhealthy, adult
n = 813
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 813
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
Aggressive behavior
2500 mg 1 times / day multiple, oral
Overdose
Dose: 2500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2500 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
unhealthy
Health Status: unhealthy
Condition: epilepsy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
Agitation
2500 mg 1 times / day multiple, oral
Overdose
Dose: 2500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2500 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
unhealthy
Health Status: unhealthy
Condition: epilepsy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
Irritability
2500 mg 1 times / day multiple, oral
Overdose
Dose: 2500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2500 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
unhealthy
Health Status: unhealthy
Condition: epilepsy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1767
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2A6
707

CYP2C8
911

CYP2C19
1478

CYP2E1
882

CYP3A4/5
278

P-gp
1461
UGT1A1
418

UGT1A3
422

UGT1A9
380

UGT1A4
347

UGT1A6
307

UGT1A7
236

UGT1A10
291

UGT2B4
249

UGT2B7
389

UGT2B15
203

CYP 450
31

P-gp
1537
CYP1A2
701

CYP3A4/5
124

CYP2C
15

P-gp
257
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1650
 likely
N-AMR
3
CYP1A2
1692
 no
CYP1A2
1692
 no
CYP2A6
739
 no
CYP2C
34
 no
CYP2C19
1553
 no
CYP2C8
965
 no
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP2E1
970
 no
CYP3A4/5
335
 no
CYP3A4/5
335
 no
P-gp
1650
 no
P-gp
1650
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP 450
31
 no evidence
P-gp
1537
 no
UGT1A10
291
 no
UGT1A6
307
 no
UGT1A7
236
 no
UGT2B15
203
 no
UGT2B4
249
 no
UGT2B7
389
 no
UGT1A3
422
 yes
UGT1A4
347
 yes
UGT1A9
380
 yes
UGT1A1
418
 yes
no (pharmacogenomic study)
Comment: AUC of the acetylated metabolite was higher in subjects with UGT1A1*28 mutation versus subjects with UGT1A1 wildtype. The differences in PK parameters do not warrant dose change recommendations.
Page: 14.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:68584
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:68584
ChemicalBook
CB7506804
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7506804
MolPort
MolPort-003-850-148
https://www.molport.com/shop/molecule-link/MolPort-003-850-148
ZINC
ZINC000000016154
http://zinc15.docking.org/substances/ZINC000000016154
eMolecules
2729733
https://www.emolecules.com/cgi-bin/more?vid=2729733
PubMed

PubMed

TitleDatePubMed
Retigabine (ASTA Medica).
2001 Jan
Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats.
2004 Nov
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).
2004 Sep-Oct
Ion channel defects in idiopathic epilepsies.
2005
Ion channels and epilepsy.
2005
Voltage gated ion channels: targets for anticonvulsant drugs.
2005
The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate.
2005 Apr
Effects of anticonvulsants on soman-induced epileptiform activity in the guinea-pig in vitro hippocampus.
2005 Aug 22
Gateways to clinical trials.
2005 Jan-Feb
Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels.
2005 Jul
Presynaptic inhibition of transmitter release from rat sympathetic neurons by bradykinin.
2005 Jun
The KCNQ5 potassium channel from mouse: a broadly expressed M-current like potassium channel modulated by zinc, pH, and volume changes.
2005 Sep 13
Retigabine: bending potassium channels to our will.
2005 Sep-Oct
Retigabine: chemical synthesis to clinical application.
2005 Spring
[Voltage-activated potassium channels of the inhibitory interneurons of the hippocampus in culture].
2006
Retigabine: in partial seizures.
2006
Gateways to clinical trials.
2006 Apr
New antiepileptic drugs that are second generation to existing antiepileptic drugs.
2006 Jun
KCNQ channels mediate IKs, a slow K+ current regulating excitability in the rat node of Ranvier.
2006 May 15
Antidystonic effects of Kv7 (KCNQ) channel openers in the dt sz mutant, an animal model of primary paroxysmal dystonia.
2006 Nov
Somatodendritic Kv7/KCNQ/M channels control interspike interval in hippocampal interneurons.
2006 Nov 22
Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release.
2006 Oct 1
Retigabine-induced population primary afferent hyperpolarisation in vitro.
2006 Sep
The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat.
2006 Sep
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
2007 Apr 10
Recruitment of apical dendritic T-type Ca2+ channels by backpropagating spikes underlies de novo intrinsic bursting in hippocampal epileptogenesis.
2007 Apr 15
Inactivation as a new regulatory mechanism for neuronal Kv7 channels.
2007 Apr 15
A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives.
2007 Dec 26
Kv7.2-7.5 voltage-gated potassium channel (KCNQ2-5) opener, retigabine, reduces capsaicin-induced visceral pain in mice.
2007 Feb 14
Retigabine.
2007 Jan
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).
2007 Jan
Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels.
2007 May
Phenytoin- and carbamazepine-resistant spontaneous bursting in rat entorhinal cortex is blocked by retigabine in vitro.
2007 May
Peripheral nerve hyperexcitability due to dominant-negative KCNQ2 mutations.
2007 Nov 27
Retigabine: has the orphan found a home?
2007 Nov-Dec
Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety.
2007 Oct
The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine.
2007 Sep 10
The effectiveness of anticonvulsants in psychiatric disorders.
2008
Nervous system KV7 disorders: breakdown of a subthreshold brake.
2008 Apr 1
The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease.
2008 Feb
The KCNQ/M-current modulates arterial baroreceptor function at the sensory terminal in rats.
2008 Feb 1
Effect of the new antiepileptic drug retigabine in a rodent model of mania.
2008 Jan
Expression profile and characterisation of a truncated KCNQ5 splice variant.
2008 Jul 11
Retigabine reduces the excitability of unmyelinated peripheral human axons.
2008 Jun
Gateways to clinical trials.
2008 Mar
Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study.
2008 Oct
Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents.
2008 Sep
Retigabine, the specific KCNQ channel opener, blocks ectopic discharges in axotomized sensory fibres.
2008 Sep 15
Expression and function of K(v)7 channels in murine myometrium throughout oestrous cycle.
2009 Mar
Patents

Patents

US2006258712
3
US2007225274
3
US2010015228
3
US2010160411
3
US7365095
3
US7368477
3
US7501414
3
US7906537
3
US8017772
3

Sample Use Guides

In Vivo Use Guide
Potiga should be given orally in 3 equally divided doses daily, with or without food. The initial dosage should be 100 mg 3 times daily (300 mg per day) and should be increased gradually at weekly intervals by no more than 50 mg 3 times daily (increase in the daily dose of no more than 150 mg per day) up to a maintenance dosage of 200 mg to 400 mg 3 times daily (600 mg to 1,200 mg per day), based on individual patient response and tolerability.
Route of Administration: Oral
In Vitro Use Guide
KCNQ4 channels, stably expressed in HEK293 cells, were activated by retigabine (ezogabine) in a reversible and concentration-dependent manner in the concentration range 0.1-10 uM. Retigabine shifted the KCNQ4 channel activation curves towards more negative potentials by about 10 mV.
Name Type Language
EZOGABINE
DASH   MI   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
RETIGABINE
EMA EPAR   INN   MART.   WHO-DD  
INN  
Official Name English
Retigabine [WHO-DD]
Common Name English
POTIGA
Brand Name English
AWD-21360
Code English
XEN-496
Code English
GW582892X
Code English
EZOGABINE [MI]
Common Name English
TROBALT
Brand Name English
GKE-841
Code English
EZOGABINE [VANDF]
Common Name English
GW-582892X
Code English
RETIGABINE [MART.]
Common Name English
retigabine [INN]
Common Name English
AWD21-360
Code English
CARBAMIC ACID, (2-AMINO-4-(((4-FLUORO-PHENYL)METHYL)AMINO)PHENYL)-ETHYL ESTER
Systematic Name English
RETIGABINE [EMA EPAR]
Common Name English
XEN496
Code English
D-23129
Code English
WAY-143841
Code English
EZOGABINE [ORANGE BOOK]
Common Name English
N-[2-Amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester
Systematic Name English
EZOGABINE [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000182729
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
DEA NO. 2779
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
EMA ASSESSMENT REPORTS TROBALT (AUTHORIZED: EPILEPSY)
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
FDA ORPHAN DRUG 639118
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
WHO-VATC QN03AX21
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
NCI_THESAURUS C264
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
WHO-ATC N03AX21
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
LIVERTOX NBK548304
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
Code System Code Type Description
PUBCHEM
121892
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
MERCK INDEX
m5229
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY Merck Index
HSDB
8171
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
WIKIPEDIA
Retigabine
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
IUPHAR
2601
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
LACTMED
Ezogabine
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
INN
7545
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
CHEBI
68584
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
SMS_ID
100000080573
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
CAS
150812-12-7
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
USAN
SS-10
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
DRUG CENTRAL
4181
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
NCI_THESAURUS
C72839
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
EVMPD
SUB10291MIG
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
RXCUI
1112990
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY RxNorm
NDF-RT
N0000182728
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY Potassium Channel Openers [MoA]
EPA CompTox
DTXSID40164615
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
DRUG BANK
DB04953
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
ChEMBL
CHEMBL41355
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
FDA UNII
12G01I6BBU
Created by admin on Sat Dec 16 16:54:06 GMT 2023 , Edited by admin on Sat Dec 16 16:54:06 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of EZOGABINE
SALT/SOLVATE (PARENT)
Structure of EZOGABINE DIHYDROCHLORIDE
SALT/SOLVATE (PARENT)
Structure of EZOGABINE HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966